Oncotarget

Clinical Research Papers:

An integrated analysis of hyponatremia in cancer patients receiving platinum-based or nonplatinum-based chemotherapy in clinical trials (JCOG1405-A)

Yasumasa Ezoe, Junki Mizusawa, Hiroshi Katayama, Kozo Kataoka and Manabu Muto _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:6595-6606. https://doi.org/10.18632/oncotarget.23536

Metrics: PDF 1949 views  |   HTML 2973 views  |   ?  


Abstract

Yasumasa Ezoe1, Junki Mizusawa2, Hiroshi Katayama2, Kozo Kataoka2 and Manabu Muto1

1Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

2Japan Clinical Oncology Group (JCOG) Data Center/Operations Office, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Correspondence to:

Manabu Muto, email: [email protected]

Keywords: hyponatremia; platinum agent; cisplatin; carboplatin; risk factors

Abbreviations: JCOG: Japan Clinical Oncology Group; SIADH: syndrome of inappropriate antidiuretic hormone secretion; NCI-CTC: National Cancer Institute-Common Toxicity Criteria; CI: confidence interval

Received: October 27, 2017     Accepted: December 01, 2017     Published: December 20, 2017

ABSTRACT

Background: Hyponatremia is a common electrolyte abnormality in cancer patients who receive chemotherapy. Among anticancer agents, platinum-based agents are reported to cause chemotherapy-induced hyponatremia. However, the actual incidence and risk factors remain unknown.

Results: The reports of 29 trials were analyzed. The incidence of grade 3/4 hyponatremia was 11.9% in patients treated with platinum-based chemotherapy and 3.8% in those treated with nonplatinum-based regimens (P < 0.01). Univariable analysis revealed a high incidence of hyponatremia in patients receiving cisplatin, three-drug combination regimen, two-drug combination regimen with amrubicin or irinotecan, or high-dose cisplatin (weekly equivalent cisplatin dose ≥20 mg/m2), and in patients with small-cell lung cancer.

Conclusion: This is the first report of the actual incidence and the potential risk factors of chemotherapy-induced hyponatremia. Careful monitoring of serum sodium level is needed when platinum-based chemotherapy is administered.

Methods: This study included all clinical trials of systemic chemotherapies for solid cancers that were conducted by the Japan Clinical Oncology Group (JCOG) after January 2000 and of which the patient enrolment was completed by January 2014. The latest reports of each trial were used for analysis. The incidence of chemotherapy-induced grade 3/4 hyponatremia and the potential risk factors were investigated with univariable analysis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23536